Access cutting-edge her2+ cancer treatment through this clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.
Access her2+ cancer specialists in Los Angeles at no cost
This study follows strict safety protocols and ethical guidelines
All study-related her2+ cancer treatment provided free
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not successful. The purpose of this study is to find a suitable dose of zongertinib that people with different types of HER2+ cancer that has spread can tolerate best when taken together with trastuzumab deruxtecan (T-DXd), with trastuzumab emtansine (T-DM1),
Sponsor: Boehringer Ingelheim
Check if you qualify for this her2+ cancer clinical trial in Los Angeles, CA
If you're searching for her2+ cancer treatment options in Los Angeles, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Los Angeles research site is actively enrolling participants for this clinical trial. You'll receive care from experienced her2+ cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.